Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
According to a new report from Bloomberg, Mylan NV has a new plan to further ubiquitize its cash cow EpiPen: cut out pharmacies as the middleman and sell the drug directly to public places.
Utilizing a similar strategy to its push to get EpiPens stocked in schools nationwide, Mylan is intensely lobbying state officials around the country to approve legislation allowing "entity prescriptions." No state allowed these sales prior to Mylan's push — now more than 30 are on board.
Why it matters: Mylan's idea has the potential to revolutionize how medicines, especially those that might be needed in a public space, are sold. At the expense of traditional pharmacies, buying EpiPens directly from Mylan would cut the product's price by more than half for the consumer, while still allowing Mylan to make the same profit.